[Causality between atopic diseases and osteoarthritis:a Mendelian randomization study].

Zhongguo Gu Shang

Beijing University of Chinese Medicine, Beijing 100029, China; Guang'anmen Hospital, China Academy of Traditional Chinese Medicine, Beijing 100053, China.

Published: September 2024

Objective: To explore causal relationship between atopic diseases (asthma and atopic dermatitis) and osteoarthritis (OA) by using mendelian randomization(MR).

Methods: Asthma and atopic dermatitis as instrumental variables were selected, searched them through IEU database, and selected the latest data with a large number of cases and single nucleotide polymorphism (SNP). Data were collected and processed using R language, inverse varianceweighted (IVW) method was adopted as main MR Evaluation method. Single linear regression was performed to estimate causality based on pooled knee and hip data from genome-wide association studies (GWAS). The forest map was drawn to visualize the results, and gene pleiotropy and sensitivity were analyzed by scatter plot and funnel plot. At the same time, asthma, atopic dermatitis, body mass index (BMI), osteoporosis and OA were selected for multivariate MR Analysis to exclude the effect of horizontal pleiotropy on the results in GWAS data.

Results: Analysis of MR-IVW results showed asthma was positively correlated with causal effect of OA [=1.41, 95%(1.07, 1.85), =0.02], multivariate Mendelian randomization (MVMR) adjusted for BMI and osteoporosis and a direct causal effect on OA was observed [=1.57, 95%(1.03, 2.39), =0.03)]. MR Results of two samples of atopic dermatitis and OA were [=1.01, 95%(0.97, 1.04), =0.76], and MVMR results were [=1.02, 95%(0.99, 1.05), =0.25], indicating no clear causal relationship between two samples.

Conclusion: Asthma could increase risk of OA, atopic dermatitis has no obvious relationship with OA, and the relationship between atopic diseases and OA still needs to be discussed.

Download full-text PDF

Source
http://dx.doi.org/10.12200/j.issn.1003-0034.20230868DOI Listing

Publication Analysis

Top Keywords

atopic dermatitis
20
atopic diseases
12
asthma atopic
12
mendelian randomization
8
causal relationship
8
relationship atopic
8
bmi osteoporosis
8
atopic
7
asthma
5
dermatitis
5

Similar Publications

Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, we investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. Our findings revealed that cases who discontinued treatment with nemolizumab had more severe erythema and edema/papulation on the trunk than those who continued nemolizumab.

View Article and Find Full Text PDF

The Significant Role of Atopic Skin Diathesis in Prurigo Nodularis.

Sisli Etfal Hastan Tip Bul

December 2024

Department of Dermatology and Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.

Objectives: Atopic skin plays a significant etiological role in the development of prurigo nodularis (PN). In addition to atopic dermatitis (AD), atopic skin diathesis without eczema can also contribute to the development of PN due to its association with itching. This study aims to evaluate PN in terms of AD/atopic skin diathesis, associated comorbidities, and clinical findings.

View Article and Find Full Text PDF

Objective: To present and analyze eight clinical cases illustrating the use of rose stem cell-derived exosomes (RSCEs) in treating various dermatological conditions and to review current literature on plant-derived exosomes in medicine and dermatology.

Background: RSCEs possess low cytotoxicity, high biocompatibility, and effective cellular uptake, making them promising agents for dermatological therapies. A literature review included in the introduction and discussion covers the broader role of plant-derived exosomes, highlighting their therapeutic potential in skin treatment.

View Article and Find Full Text PDF

Quality of Life in Adults with Atopic Dermatitis in Relation to Disease Severity: Nationwide Data in Japan.

Dermatol Ther (Heidelb)

January 2025

Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo, 108-8241, Japan.

Introduction: The impact of atopic dermatitis (AD) on daily life and different levels of quality of life (QOL) according to AD severity has not been fully elucidated. This study aimed to assess QOL in relation to the AD severity in Japan.

Methods: This observational study used anonymized data of health insurance association members and their families registered to a mobile health app.

View Article and Find Full Text PDF

Introduction: Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of upadacitinib in real-world settings over a period of 96 weeks.

Methods: This retrospective study included all patients treated with upadacitinib at our centre between April 2022 and September 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!